There are 2789 resources available
262P - Pattern of failure and treatment results in triple-negative breast cancer patients
Presenter: Sherif Farouk El Zawawy
Session: ePoster Display
263P - Predicting bevacizumab efficacy in mTNBC
Presenter: Heba Bakri
Session: ePoster Display
264P - AMEERA-1: Subgroup analyses of phase I/II study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (aBC)
Presenter: Sarat Chandarlapaty
Session: ePoster Display
267P - Phase Ib/II open-label, randomized evaluation of second- or third-line (2L/3L) atezolizumab (atezo) + entinostat (entino) in MORPHEUS-HR+ breast cancer (M-HR+BC)
Presenter: Amir Sonnenblick
Session: ePoster Display
268P - Anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple-negative, EGFR positive breast cancer: A multicenter single arm phase II trial [SAKK 24/14]
Presenter: Andreas Wicki
Session: ePoster Display
269P - Patient-reported outcomes (PRO) with talazoparib (TALA) vs physician’s choice chemotherapy (PCT) in patients (pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm): Subgroup analysis of pts with and without TALA dose reductions vs PCT in the EMBRACA trial
Presenter: Hope Rugo
Session: ePoster Display
270P - Phase Ib study of venadaparib, a potent and selective PARP inhibitor, in homologous recombination repair (HRR) mutated breast cancer
Presenter: Seock-Ah Im
Session: ePoster Display
271P - First-in-human, phase I dose escalation and expansion study of anti-HER2 ADC MRG002 in patients with HER2 positive solid tumors
Presenter: Ye Guo
Session: ePoster Display